Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/163657
Title: mRNA booster vaccination enhances antibody responses against SARS-CoV2 omicron variant in individuals primed with mRNA or inactivated virus vaccines
Authors: Zhang, Biyan
Huo, Jianxin
Huang, Yuhan
Teo, Shuan Yong
Duan, Kaibo
Li, Yanfeng
Toh, Lim Kai
Lam, Kong Peng
Xu, Shengli
Keywords: Science::Biological sciences
Science::Medicine
Issue Date: 2022
Source: Zhang, B., Huo, J., Huang, Y., Teo, S. Y., Duan, K., Li, Y., Toh, L. K., Lam, K. P. & Xu, S. (2022). mRNA booster vaccination enhances antibody responses against SARS-CoV2 omicron variant in individuals primed with mRNA or inactivated virus vaccines. Vaccines, 10(7), 1057-. https://dx.doi.org/10.3390/vaccines10071057
Journal: Vaccines 
Abstract: The advent of the Omicron variant globally has hastened the requirement for a booster vaccination dose to confer continuous protection against symptomatic SARS-CoV2 infection. However, different vaccines are available in different countries, and individuals who had adverse reactions to certain vaccine types require heterologous vaccine boosters. To understand the efficacy of different vaccination regimens in inducing humoral responses to SARS-CoV2, we examined plasma antibodies and frequencies of Omicron RBD-specific B cells in individuals who had different priming-booster vaccination regimens. We found that individuals with three homologous doses of mRNA vaccines had higher levels of IgG of all subclasses against RBD of Omicron than individuals with three homologous doses of inactivated virus vaccine. A booster with mRNA vaccine resulted in significant increases in median levels of RBD-reactive IgG1 (17-19 fold) and IgG3 (2.3-3.3 fold) as compared to individuals receiving inactivated virus booster shots regardless of priming vaccine types. More importantly, individuals who received a booster dose of mRNA vaccine, irrespective of the priming vaccine, had antibodies with higher neutralizing capability against the Omicron variant than those who received a booster dose of inactivated virus vaccine. Corroborating the antibody results, boosting with the mRNA vaccine increased the frequencies of Omicron RBD-binding B cells by (1.5-3.3 fold) regardless of priming vaccine types. Together, our data demonstrate that an mRNA vaccine (BNT162b2 or mRNA-1273) booster enhances humoral responses against the Omicron variant in individuals vaccinated with either two prior doses of mRNA or inactivated virus vaccine (CoronaVac or BBIBP-CorV), potentially providing more effective protection against SARS-CoV-2 infection, particularly by the Omicron variant.
URI: https://hdl.handle.net/10356/163657
ISSN: 2076-393X
DOI: 10.3390/vaccines10071057
Schools: School of Biological Sciences 
Organisations: Singapore Immunology Network, A*STAR
Yong Loo Lin School of Medicine, NUS
Rights: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SBS Journal Articles

Files in This Item:
File Description SizeFormat 
vaccines-10-01057-v2.pdf2.67 MBAdobe PDFThumbnail
View/Open

SCOPUSTM   
Citations 50

6
Updated on Feb 22, 2024

Web of ScienceTM
Citations 50

4
Updated on Oct 25, 2023

Page view(s)

129
Updated on Feb 26, 2024

Download(s) 50

23
Updated on Feb 26, 2024

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.